European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ECIL 32009 update

Bone Marrow Transplantation

Volumn 46, Issue 5, 2011, Pages 709-718

  Maertens, J ^a   Marchetti, O ^b   Herbrecht, R ^c   Cornely, O A ^d   Fluckiger U ^e   Frre, P ^f   Gachot, B ^g   Heinz, W J ^h   Lass Florl C ⁱ   Ribaud, P ^j   Thiebaut, A ^k   Cordonnier, C ^l  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f Hematology Department   (Belgium)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h UNIVERSITY OF WÜRZBURG   (Germany)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j SAINT LOUIS HOSPITAL   (France)

^k GRENOBLE UNIVERSITY HOSPITAL   (France)

^l HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

antifungals; Aspergillus; Candida; leukemia; neutropenia; SCT

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CHILL; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG FEVER; DRUG WITHDRAWAL; EUROPE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOXIA; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LEUKEMIA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; SECONDARY PREVENTION; SYSTEMIC MYCOSIS; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 79955898005     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.175     Document Type: Article

References (46)

1. Maertens J, Frere P, Lass-Flörl C, Heinz W, Cornely OA. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer 2007; Suppl 5: 43-48 (Pubitemid 47193191)
2. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropenic cancer patients with persistent fever. Eur J Cancer 2007; Suppl 5: 32-42 (Pubitemid 47187743)
3. Herbrecht R, Flückiger U, Gachot B, Ribaud P, Tiebaut A, Cordonnier C. Treatment of invasive candida and invasive aspergillus infections in adult haematological patients. Eur J Cancer 2007; Suppl 5: 49-59 (Pubitemid 47187744)
4. ECIL Guidelines for the management of bacterial, fungal and viral infections 2009. http://www.ichs.org/Ecilslides/ECIL% 203%20Empirical%20Antifungal%20Therapy%20Update %202009.pdf
5. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535
6. Walsh TJ, Anaissie EJ, Dennin DW, Herbrecht R, Kontoyaiannis DP, Marr K et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360 (Pubitemid 351265310)
7. Cordonnier C, Calandra T. The first European Conference on infections in leukaemia: why and how? Eur J Cancer 2007; Suppl 5: 2-4 (Pubitemid 47187739)
8. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32: 851-854 (Pubitemid 32524817)
9. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851
10. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasisrelated death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-2061
11. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation- a prospective, randomized double blind study. J Infect Dis 1995; 171: 1545-1552
12. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347 (Pubitemid 46148776)
13. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 34
14. Marks DI, Kibbler C, Pagliugi A, Ribaud P, Solano C, Heussel CP et al. Voriconazole vs Itraconazole for primary prophylaxis of invasive fungal infection in allogeneic hematopoietic cell transplant (HCT) recipients. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009; San Francisco, CA 2009
15. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID et al. Results of a randomized, double-blind trial of Fluconazole vs Voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients. In: 49th American Society of Hematology Annual Meeting and Exposition; 2007. American Society of Hematology: Atlanta, GA, 2007, p 163
16. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1401-1408 (Pubitemid 351589940)
17. Fukuda T, Boeckh M, Guthrie K, Mattson DK, Owens S, Wald A et al. Invasive aspergillosis before allogeneic hematopoetic stem cell transplantation: 10 year experience at a single transplant center. Biol Bone Marrow Transplant 2004; 10: 494-503 (Pubitemid 38772003)
18. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A et al. Impact of the intensity of the pretransplant conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928-2936
19. Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K et al. Voriconazole for secondary prophylaxis of invasive fungal infection in allogeneic stem cell transplant recipients: results of the VOSIFI study. Hematologica 2010 (in press)
20. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D et al. Liposomal Amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-771 (Pubitemid 29114295)
21. Walsh TJ, Teppler H, Donowitz GR, Maertens J, Baden LR, Dmoszynska A et al. Caspofungin versus liposomal Amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402
22. Tamura K, Urabe A, Yoshida M, Kanamaru A, Kodera Y, Okamoto S et al. Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma 2009; 50: 92-100
23. Kubiak X. Caspofungin vs micafungin for empirical therapy in adult neutropenic patients with persistent fever: a retrospective analysis. In: 48th ICAAC; 2008. Washington, DC, 2008
24. Maertens J, Madero-Lopez L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS; et al. Caspofungin vs liposomal AmB for empirical therapy in pediatric neutropenic patients with persistent fever: a randomized, double-blind, multicenter trial. Pediatr Infect Dis J 29: 415-420
25. Ohta K, Kosaka SN, Nakao Y, Kumura T, Hagihara K, Sakamoto E et al. Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan. Int J Hematol 2009; 89: 649-655
26. Lafaurie M, Lapalu J, Raffoux E, Breton B, Lacroix C, Socié G et al. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect 2009 (e-pub ahead of print 3 September 2009)
27. Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostics adjuncts. Clin Infect Dis 2007; 44: 402-409 (Pubitemid 46147624)
28. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-1250 (Pubitemid 41534660)
29. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F et al. Empirical versus pre-emptive antifungal strategy in high-risk febrile neutropenic patients: a prospective randomized study. Clin Infect Dis 2009; 48: 1042-1051
30. Hebart H, Klingspor L, Klingebiel T, Loeffler J, Tollemar J, Ljungman P et al. A prospective ranomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allogeneic stem cell transplant. Bone Marrow Transplant 2008; 43: 553-561
31. Riva E, Nosari A, Brizio A, Molteni A, Vanelli C, Gabutti C et al. In high risk acute leukemia patients, early antifungal therapy improves the outcome of invasive mould infections. In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008, Chicago, IL 2008
32. Aguilar-Guisado M, Espigado I, Cordero E, Noguer N, Parody R, Pachon J et al. Empirical antifungal therapy in selected patients with persistent febrile neutropenia. Bone Marrow Transplant 2010; 45: 159-164
33. Barnes RA, White PL, Bygrave C, Evans N, Healy B, Kell J. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol 2009; 62: 64-69
34. Dignan FL, Evans SO, Ethell ME, Shaw BE, Davies FE, Dearden CE et al. An early CT-diagnosis based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant 2009; 44: 51-56
35. Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2010; 28: 667-674
36. Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64: 1274-1281
37. Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: a European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010 (e-pub ahead of print 11 January 2010; doi:10.1038/bmt.2009.334)
38. Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Aliff C et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 2008; 112: 1282-1287 (Pubitemid 351429743)
39. Cesaro S, Giacchino M, Locatelli F, Spiller M, Buldini B, Castellini C et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis 2007; 18: 28
40. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ et al. A multicenter, double-blind trial of a highdose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-1684
41. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415 (Pubitemid 34851833)
42. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson- Moya L, Smietana J et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029 (Pubitemid 35461658)
43. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-1442 (Pubitemid 41483809)
44. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482 (Pubitemid 46919773)
45. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-1527 (Pubitemid 46670281)
46. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-893 (Pubitemid 47580382)